C. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.

C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.

C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.

C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.

C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.

C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.

C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.

C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.

C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.

C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.